跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 12 天前AI 评分55

FDA 调查诺华 Zolgensma 与癌症风险相关性

FDA launches investigation of Novartis’ Zolgensma after cancer cases

AI 导读

FDA 正在调查诺华的脊髓性肌萎缩基因疗法 Zolgensma 与严重癌症风险的相关性。

正文

The FDA is look­ing in­to a “se­ri­ous risk” of can­cer linked to No­var­tis’ spinal mus­cu­lar at­ro­phy gene ther­a­py Zol­gens­ma, the agency

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news